GreenMark’s dental treatments will be developed in partnership with University of Michigan, which has backed the company’s two-tranche seed round through its Mints Fund.

The firm’s portfolio fell to a $61.8m net loss during 2018 amid difficult market conditions for listed small-cap businesses and the consolidation of its former peer Touchstone Innovations.

Perspectives on sustainability and wellbeing are changing in response to health and environmental challenges, offering an opportunity to university-linked businesses.

Elaine Jones, vice-president at pharmaceutical company Pfizer’s corporate venture capital unit, has shared highlights of her career with GCV ahead of her departure in April.

The CNPG-backed oncology therapy developer boosted its overall funding to $70m in a round backed by Eli Lilly and CICC Capital.

Amgen Ventures, MRL Ventures Fund and Pharmaron contributed to a round that almost doubled the total raised by the bone marrow disease drug developer since 2012.

University of Delaware-backed science incubator Delaware Innovation Space has started a VC vehicle called First Fund offering startups up to $75,000 in convertible notes.

Eli Lilly and GlaxoSmithKline-backed cancer treatment developer Turning Point Therapeutics has filed to raise up to $100m having secured $145m in VC funding.

Pharmaceutical firm Pfizer has acquired a 15% stake in the gene therapy developer along with an exclusive option to fully buy the Novartis-backed company.

The immunotherapy developer, which is majority owned by BGI Group, has secured $17.8m in a GF Securities-led round that will fund clinical work on its lead product candidate.